SAN DIEGO, June 7, 2011 /PRNewswire/ — bioTheranostics, Inc., a
bioMerieux company that develops innovative oncology diagnostic
tests to drive personalized treatment, reported today findings from
clinical studies utilizing the company’s CancerTYPE ID®, and
Breast Cancer Index(SM). Data from the studies were presented this
week at the American Society of Clinical Oncology (ASCO) 2011
Annual Meeting in Chicago.
On June 6, scientists from bioTheranostics and the Institut
Gustave-Roussy (France) presented results from a study evaluating
the utility of the Breast Cancer Index(SM) (BCI) for predicting
pathologic complete response (pCR) in breast cancer patients
treated with neoadjuvant chemotherapy. In the study, patients
with a high BCI score had a more favorable response to standard
chemotherapies such as anthracycline and taxane (P=0.02).
“Patients determined as high-risk by BCI had a 10-fold greater
probability of pCR with the chemotherapy regimen when compared to
the low risk patients,” said Mark Erlander, Ph.D., chief scientific
officer, bioTheranostics. “These results suggest that BCI is
predictive of chemotherapy response.”
bioTheranostics also presented diagnostic utility data for
CancerTYPE ID® from a study of 754 metastatic cancer cases.
The results showed that pre-CancerTYPE ID® pathological
workup involved a mean of seven immunohistochemistry (IHC) stains
to identify the cancer site of origin. Increasing the number
of IHC stains beyond seven lengthened the diagnostic process
without improving the accuracy of the final result.
“Quickly and accurately diagnosing the site of origin is
critical in the care of metastatic cancer patients,” said Richard
Ding, chief executive officer, bioTheranostics. “This study
illustrated that the current diagnostic process is not standardized
and often time- consuming.” In the study, CancerTYPE ID
required only five days of lab processing to predict a
‘/>”/>
